Search Results - "Freedman, M S"

Differential diagnosis of suspected multiple sclerosis: a consensus approach by Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH

“…Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings…”
Get full text

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes by KAPPOS, L, POLMAN, C. H, POHL, C, SANDBRINK, R, FREEDMAN, M. S, EDAN, G, HARTUNG, H. P, MILLER, D. H, MONTALBAN, X, BARKHOF, F, BAUER, L, JAKOBS, P

“…To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple…”
Get full text

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis by Das, J, Snowden, JA, Burman, J, Freedman, MS, Atkins, H, Bowman, M, Burt, RK, Saccardi, R, Innocenti, C, Mistry, S, Laud, PJ, Jessop, H, Sharrack, B

“…Background: Autologous haematopoietic stem cell transplantation (AHSCT) is an effective treatment for patients with multiple sclerosis (MS) who have highly…”
Get full text

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS by FREEDMAN, M. S, BAR-OR, A, FERENCZI, L, VERCO, T, OGER, J, TRABOULSEE, A, PATRY, D, YOUNG, C, OLSSON, T, LI, D, HARTUNG, H.-P, KRANTZ, M

“…To evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS) who express human leukocyte antigen (HLA)…”
Get full text

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses by O'CONNOR, P. W, LI, D, FREEDMAN, M. S, BAR-OR, A, RICE, G. P. A, CONFAVREUX, C, PATY, D. W, STEWART, J. A, SCHEYER, R

“…Teriflunomide, a dihydro-orotate dehydrogenase inhibitor, has immunomodulatory effects, including the ability to suppress experimental allergic…”
Get full text

Teriflunomide added to interferon-β in relapsing multiple sclerosis: A randomized phase II trial by FREEDMAN, M. S, WOLINSKY, J. S, SIMONSON, C, O'CONNOR, P. W, WAMIL, B, CONFAVREUX, C, COMI, G, KAPPOS, L, OLSSON, T. P, MILLER, A, BENZERDJEB, H, LI, H

“…To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon-β (IFNβ) in patients with relapsing forms of multiple sclerosis (RMS). A total…”
Get full text

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper by Saccardi, R, Freedman, MS, Sormani, MP, Atkins, H, Farge, D, Griffith, LM, Kraft, G, Mancardi, GL, Nash, R, Pasquini, M, Martin, R, Muraro, PA

“…Background: Haematopoietic stem cell transplantation (HSCT) has been tried in the last 15 years as a therapeutic option in patients with poor-prognosis…”
Get full text

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis : A dose-finding trial by FAZEKAS, F, LUBLIN, F. D, LI, D, FREEDMAN, M. S, HARTUNG, H. P, RIECKMANN, P, SOELBERG SØRENSEN, P, MAAS-ENRIQUEZ, M, SOMMERAUER, B, HANNA, K

“…Several studies have reported a reduction of relapses after the long-term administration of IV immunoglobulin (IVIG) to patients with relapsing-remitting…”
Get full text

Detecting cognitive fatigue in multiple sclerosis: Method matters by Walker, L.A.S, Berard, J.A, Berrigan, L.I, Rees, L.M, Freedman, M.S

“…Abstract Background Fatigue is a frequently reported and debilitating symptom in multiple sclerosis (MS). Cognitive fatigue (CF) can be defined as decreased…”
Get full text

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis by Vollmer, T, Panitch, H, Bar-Or, A, Dunn, J, Freedman, MS, Gazda, SK, Campagnolo, D, Deutsch, F, Arnold, DL

“…Forty relapsing multiple sclerosis patients with 1–15 gadolinium (Gd)-enhancing lesions on screening brain magnetic resonance imaging (MRI) and Expanded…”
Get full text

Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years by MacMillan, EL, Tam, R, Zhao, Y, Vavasour, IM, Li, DKB, Oger, J, Freedman, MS, Kolind, SH, Traboulsee, AL

“…Background: Few biomarkers of progressive multiple sclerosis (MS) are sensitive to change within the two-year time frame of a clinical trial. Objective: To…”
Get full text

Interferon β-1b―neutralizing antibodies 5 years after clinically isolated syndrome by HARTUNG, H.-P, FREEDMAN, M. S, SAHAJPAL, V, KNAPPERTZ, V, BECKMANN, K, LANIUS, V, SANDBRINK, R, POHL, C, POLMAN, C. H, EDAN, G, KAPPOS, L, MILLER, D. H, MONTALBAN, X, BARKHOF, F, PETKAU, J, WHITE, R

“…To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with…”
Get full text

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis by Hartung, H-P, Berger, T, Bermel, RA, Brochet, B, Carroll, WM, Holmøy, T, Karabudak, R, Killestein, J, Nos, C, Patti, F, Ross, A Perrin, Vanopdenbosch, L, Vollmer, T, Buffels, R, Garas, M, Kadner, K, Manfrini, M, Wang, Q, Freedman, MS

“…•Infusion-related reaction rates were similar in shorter and conventional infusions•The majority of infusion-related reactions were mild to moderate•No…”
Get full text

Anti-α-glucose–based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event by Freedman, MS, Laks, J, Dotan, N, Altstock, RT, Dukler, A, Sindic, CJM

“…Background There is no specific serum-based biomarker for the diagnosis or prognosis of relapsing-remitting multiple sclerosis (RRMS). Objective We…”
Get full text

The challenge of follow-on biologics for treatment of multiple sclerosis by REINGOLD, S. C, STEINER, J. P, POLMAN, C. H, COHEN, J. A, FREEDMAN, M. S, KAPPOS, L, THOMPSON, A. J, WOLINSKY, J. S

“…Intellectual property protections for biologic medicinals for multiple sclerosis (MS) are beginning to expire, opening the possibility of development,…”
Get full text

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis by Freedman, MS, Metzig, C, Kappos, L, Polman, CH, Edan, G, Hartung, H-P, Miller, DH, Montalban, X, Yarden, J, Spector, L, Fire, E, Dotan, N, Schwenke, S, Lanius, V, Sandbrink, R, Pohl, C

“…Background: Higher serum levels of at least one of a panel of four α-glucose IgM antibodies (gMS-Classifier1) in clinically isolated syndrome (CIS) patients…”
Get full text

Regulation of Mammalian Circadian Behavior by Non-rod, Non-cone, Ocular Photoreceptors by Freedman, Melanie S., Lucas, Robert J., Soni, Bobby, von Schantz, Malcolm, Muñoz, Marta, David-Gray, Zoë, Foster, Russell

“…Circadian rhythms of mammals are entrained by light to follow the daily solar cycle (photoentrainment). To determine whether retinal rods and cones are…”
Get full text

Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study by Freedman, M S, Forrestal, F G

“…Early intervention with an effective disease-modifying drug (DMD) offers the best chance of limiting the inflammatory process that contributes to irreversible…”
Get full text

Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion by Chen, J.T., Kuhlmann, T., Jansen, G.H., Collins, D.L, Atkins, H.L., Freedman, M.S., O’Connor, P.W., Arnold, D.L.

“…We present a new method for advanced image processing to separately quantify significant decreases and increases in the magnetization transfer ratio (MTR) of…”
Get full text

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy by Freedman, M. S.

“…Background and purpose Although the first‐line disease‐modifying therapies (DMTs) interferon beta and glatiramer acetate have a favourable benefit‐to‐risk…”
Get full text